Zhu, A. X., Nipp, R. D., Finn, R. S., Galle, P. R., Llovet, J. M., Blanc, J., . . . Kudo, M. (2020). Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: Patient-reported outcomes across two randomised clinical trials. ESMO Open.
Stile di citazione ChicagoZhu, Andrew X., et al. "Ramucirumab in the Second-line for Patients With Hepatocellular Carcinoma and Elevated Alpha-fetoprotein: Patient-reported Outcomes Across Two Randomised Clinical Trials." ESMO Open 2020.
Citazione MLAZhu, Andrew X., et al. "Ramucirumab in the Second-line for Patients With Hepatocellular Carcinoma and Elevated Alpha-fetoprotein: Patient-reported Outcomes Across Two Randomised Clinical Trials." ESMO Open 2020.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.